NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (RDY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980. The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on SGYP sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

NEW YORK, NY / ACCESSWIRE / July 26, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (RDY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980. The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

The Hyderabad, India-based company said it had net income of 40 cents per share. The pharmaceutical posted revenue of $543 million in the period. Doctor Reddy's shares have dropped 19 percent since the ...

Net profit came in at 4.76 billion rupees ($69.31 million) in the quarter ended June 30, compared with 666 million rupees a year earlier, the company said. Analysts on average had expected a net profit of 2.98 billion rupees, according to Thomson Reuters I/B/E/S. Dr.Reddy's got approval to sell versions of Indivior Plc's best-selling opioid addiction treatment last month, materially hurting the British drugmaker's revenue and forcing it to scrap its full-year forecast amid market share loss.

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version ...

NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (RDY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980. The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Dr. Reddy’s Laboratories Ltd. today announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic version of Nexium® 24HR Capsules in the United States market as approved by the U.S.

Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s” or the “Company”) (RDY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, Ext. 9980. On June 15, 2018, the U.S. District Court for the District of New Jersey granted a request by Indivior PLC (“Indivior”) for a temporary restraining order compelling Dr. Reddy’s to cease its launch activities related to the Company’s Suboxone Film product, pending resolution of Indivior’s motion for a preliminary injunction to block the product’s release. On July 13, 2018, the court granted Indivior’s motion and entered a preliminary injunction order to that effect. On this news, the price of the American depositary receipts of Dr. Reddy’s fell $3.46, or 10.41%, to close at $29.78 on July 16, 2018, the following trading day.

NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Shares of Intellia Therapeutics were in the red on Monday along with other CRISPR gene editing companies as a study found that the technique can damage DNA. CRISPR Therapeutics as well as Editas Medicine Inc. also saw losses. Dr. Reddy’s Laboratories saw losses after receiving a court order that prevents the company from selling Buprenorphine and Naloxone Sublingual Film.

A New Jersey District Court changed a temporary injunction into a preliminary injunction against the India-based company in order to stop it from releasing a generic version of Suboxone in the U.S. due to a patent case, which is still ongoing and it could affect the company’s ability to conduct business in the U.S. The case in question is US Patent No. 9,931,305 and Dr.Reddy’s Laboratories said on Saturday that it plans on appealing the decision with the U.S. District Court of New Jersey regarding any future sales and commercialization of the generic Suboxone drug, which is a sublingual film. “The company disagrees with the court’s decision, and will vigorously appeal it,” Dr. Reddy’s said.

Score one for Indivior Plc. Dr. Reddy's fell about 9% in trading Monday on the news of the preliminary injunction. The two competitors are currently embroiled in a patent-infringement lawsuit over Indivior's Suboxone sublingual film treatment since June, when Dr. Reddy's received FDA approval for its generic version.

Dr Reddy’s Laboratories Limited (NSE:DRREDDY) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. InRead More...